|
[Related PubMed/MEDLINE] Total Number of Papers: 32
|
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of |
|
|
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2020 |
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. |
--- |
2 |
2020 |
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study. |
cSLE, HC |
3 |
2020 |
The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity. |
GWs, IRs |
4 |
2020 |
Use of real-world data for HPV vaccine trial follow-up in the Nordic region. |
LTFU |
5 |
2019 |
Effectiveness of school-based and high-risk human papillomavirus vaccination programs against cervical dysplasia in Manitoba, Canada. |
ASCUS, LSILs |
6 |
2019 |
Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women. |
AEs, CIN, EGLs, SAEs |
7 |
2019 |
Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up. |
AEs, SAEs, VRCs |
8 |
2018 |
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. |
AIS |
9 |
2018 |
Early Evidence of the Effectiveness of the Human Papillomavirus Vaccination Program Against Anogenital Warts in Manitoba, Canada: A Registry Cohort Study. |
AGWs, CI, HRs |
10 |
2018 |
Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up. |
cLIA, IgG LIA |
11 |
2018 |
The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus. |
HPV, SLE |
12 |
2017 |
Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now. |
EVPI, EVPPI, HSIL, ICER, VOI |
13 |
2017 |
Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness. |
HIV, HSIL, ICER, MSM |
14 |
2017 |
Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM). |
HR-HPV, HSIL, MSM |
15 |
2017 |
Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM). |
HR-HPV, HSIL, MSM |
16 |
2017 |
Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study. |
IRRs |
17 |
2016 |
Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. |
--- |
18 |
2016 |
Quantitative benefit-risk assessment by MCDA of the quadrivalent HPV vaccine for preventing anal cancer in males. |
BR, MCDA |
19 |
2015 |
Clinical Inquiry: Does qHPV vaccine prevent anal intraepithelial neoplasia and condylomata in men? |
AIN, MSM |
20 |
2015 |
Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26years of age in Sub-Saharan Africa. |
AE, CI, HIV, HPV |
21 |
2015 |
Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. |
CI, cLIA, GMTs, HPV6, LIA, LTFU |
22 |
2015 |
Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men. |
HGAIN, HIV, MSM |
23 |
2015 |
Prevalence of Anal Human Papillomavirus Vaccine Types in the Bangkok Men Who Have Sex With Men Cohort Study. |
MSM |
24 |
2015 |
The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. |
AGW, CIs, RDs, RRs |
25 |
2014 |
Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia. |
HGAIN, HR, ICERs, LGAIN, MSM |
26 |
2014 |
Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. |
PE |
27 |
2014 |
Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men. |
MSM |
28 |
2014 |
[Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011)]. |
PCVC, SARs |
29 |
2013 |
Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. |
--- |
30 |
2011 |
Disease-specific adverse events following nonlive vaccines: a paradoxical placebo effect or a nocebo phenomenon? |
AEFIs, AR, ROR |
31 |
2011 |
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. |
CIN, EGLs |
32 |
2010 |
The quadrivalent human papillomavirus vaccine: erythema multiforme and cutaneous side effects after administration. |
EM |
|